Aralez Pharmaceuticals to acquire U.S. rights to Toprol-XL
Aralez Pharmaceuticals has reached an agreement to acquire the rights to Toprol-XL in the United States as well as its Authorized Generic from AstraZeneca. Read More »
Walgreens to honor 27,000 team members for American Pharmacists Month
Walgreens will recognize approximately 27,000 pharmacists serving communities across the country in celebration of American Pharmacists Month. Read More »
CVS Health CEO to speak about health care in Chicago
CVS Health President and CEO Larry Merlo will speak at an Executive Club of Chicago event to discuss how health care in the Untied States is accessed, delivered and financed. Read More »
Genentech's Alecensa granted Breakthrough Therapy Designation
Genentech's anaplastic lymphoma kinase inhibitor Alecensa has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Read More »
CVS Health launches October celebration for American Pharmacists Month
CVS Health has launched an October celebration to recognize the approximately 30,000 pharmacists employed in CVS Pharmacies who help people obtain better health as part of American Pharmacists Month. Read More »
Aralez launches YOSPRALA in U.S.
Aralez Pharmaceuticals' YOSPRALA -- a once-a-day medication that combines aspirin, an anti-platelet agent and omeprazole into a proton pump inhibitor (PPI) -- is now available in the United States. Read More »
TRACON completes meetings with FDA, EMA for Phase 3 TRC-105 trial
TRACON Pharmaceuticals has completed its “End-of-Phase 2” meeting with the U.S. Food and Drug Administration and its “Protocol Assistance Meeting” with the European Medicines Agency. Read More »
Eisai, Arena release BELVIQ XR weight-loss drug
Eisai Inc. and Arena Pharmaceuticals have released BELVIQ XR, a medication designed to help individuals lose weight and maintain their weight loss. Read More »
First patients enrolled in Phase 3 CAM2038 trial
Braeburn Pharmaceuticals and Camurus have enrolled the first Phase 3 CAM2038 trial patients to assess the safety and effectiveness of CAM2038 in patients with lower back pain whose present course of treatment involves opioids. Read More »
Regeneron receives positive trial results for CAPELLA
Regeneron Pharmaceutical's Phase 2 CAPELLA trial has turned in positive results. Read More »
FDA grants AbVie’s G/P regimen Breakthrough Therapy Designation
AbbVie's investigational, pan-genotype regimen of gelcaprevir (ABT-493) and pibrentasvir (ABT-530) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. Read More »
Teva launches generic version of Epzicom tablets in U.S.
Teva Pharmaceutical Industries has launched Abacavir and Iamivudine tablets, the company’s generic version of Epzicom tablets, in the United States. Read More »
Amgen's ARISE trial produces positive results
Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »
Bayer and DelSiTech announce Collaboration and Technology License Agreement
Bayer and DelSiTech have issued a joint announcement regarding the signing of a Collaboration and Technology License Agreement. Read More »
Eleventa finalizes Timapiprant trial enrollment
Eleventa, a portfolio company owned by Maxwell Biotech Venture Fund in association with its development partner Oxagen Ltd., has finalized patient enrollment for its Phase 3 Timapiprant clinical trial. Read More »
FDA gives fast-track approval for Medtronic’s MiniMed 670G
The U.S. Food and Drug Administration has given its approval of the MiniMed 670G hybrid closed looped system, designed to automatically monitor glucose and give suitable dose to individuals 14 years of age and older. Read More »
FDA approves Athersys' Multistem Phase 3 trial
The U.S. Food and Drug Administration, under a Special Protocol Assessment, has agreed to Athersys' design and analysis of a Multistem Phase 3 study. Read More »
AcelRx initiates IAP312 Phase 3 trial for study of Zalviso
AcelRx Pharmaceuticals has commenced with its IAP312 Phase 3 trial for the study of Zalviso, its new investigational product in development to treat moderate-to-severe acute pain in adult hospital patients. Read More »
Corvus releases CPI-444 Pahse 1/1b clinical study data
Corvus Pharmaceuticals has released the preclinical data and preclinical biomarker data from its Phase 1/1b CPI-444 clinical study. Read More »
FDA approves update to Rexulti label
H. Lundbeck and Otsuka Pharmaceutical Development & Commercialization have reported that the U.S. Food and Drug Administration has approved the update to the Rexulti label. Read More »
Alerts Sign-up